These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 25392999

  • 21. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T, Macdougall IC, Berns JS, Yamamoto H, Taguchi M, Iekushi K, Bernhardt T.
    Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
    [Abstract] [Full Text] [Related]

  • 22. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S, Tanaka T, Nangaku M.
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M.
    Eur J Pharmacol; 2019 Sep 15; 859():172532. PubMed ID: 31301309
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E, Cho KH, Harris ST, Flindt NR, Watt RK, Pai AB.
    Expert Opin Investig Drugs; 2020 Aug 15; 29(8):831-844. PubMed ID: 32476498
    [Abstract] [Full Text] [Related]

  • 27. Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.
    Katagiri N, Hitomi H, Mae SI, Kotaka M, Lei L, Yamamoto T, Nishiyama A, Osafune K.
    Sci Rep; 2021 Feb 16; 11(1):3936. PubMed ID: 33594180
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR.
    Am J Nephrol; 2021 Feb 16; 52(6):450-466. PubMed ID: 34280923
    [Abstract] [Full Text] [Related]

  • 30. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T, Tsubakihara Y, Nangaku M, Endo Y, Nakajima H, Kohno T, Imai Y, Kawase N, Hara K, Lepore J, Cobitz A.
    Am J Nephrol; 2017 Feb 16; 45(2):127-135. PubMed ID: 27978511
    [Abstract] [Full Text] [Related]

  • 31. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L, Locatelli F.
    Expert Opin Investig Drugs; 2018 Jul 16; 27(7):613-621. PubMed ID: 29975110
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
    Yamamoto H, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Akizawa T.
    BMJ Open; 2019 Jun 14; 9(6):e026704. PubMed ID: 31203242
    [Abstract] [Full Text] [Related]

  • 34. EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis.
    Kobayashi H, Davidoff O, Pujari-Palmer S, Drevin M, Haase VH.
    Acta Physiol (Oxf); 2022 Aug 14; 235(4):e13826. PubMed ID: 35491502
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
    Shinozaki Y, Fukui K, Kobayashi H, Yoshiuchi H, Matsuo A, Matsushita M.
    Eur J Pharmacol; 2021 May 05; 898():173990. PubMed ID: 33657422
    [Abstract] [Full Text] [Related]

  • 37. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
    Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, Lepore JJ, Cobitz AR.
    J Am Soc Nephrol; 2016 Apr 05; 27(4):1234-44. PubMed ID: 26494831
    [Abstract] [Full Text] [Related]

  • 38. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH.
    Kidney Int; 2016 Nov 05; 90(5):1115-1122. PubMed ID: 27650732
    [Abstract] [Full Text] [Related]

  • 39. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Hasegawa S, Tanaka T, Nangaku M.
    Curr Opin Nephrol Hypertens; 2018 Sep 05; 27(5):331-338. PubMed ID: 30067604
    [Abstract] [Full Text] [Related]

  • 40. [Clinical application and future perspectives of HIF-PH inhibitors].
    Nangaku M.
    Nihon Yakurigaku Zasshi; 2024 Sep 05; 159(3):157-159. PubMed ID: 38692879
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.